Aivo Biosciences, Inc.
- Biotech or pharma, therapeutic R&D
Aivo Biosciences' lead program is a novel allosteric muscarinic receptor agonist (non-PAM), initially being developed for schizophrenia. Our lead small molecule, now advancing into IND-enabling GLP toxicology studies, demonstrates superior efficacy, safety, pharmacokinetic and drug-like properties compared to xanomeline and xanomeline-based compounds, overcoming key limitations such as suboptimal efficacy, poor selectivity, short half-life, as well as tolerability / safety issues. It has high M1 potency (EC₅₀ ~1 nM), low nM M4 activity, >1000-fold selectivity over M2, M3, and M5 subtypes, and high brain penetration. The company leadership brings a proven track record in muscarinic agonist development and successfully taking biotech companies from academia to exit.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}